Federal grants to Aimmax Therapeutics Inc
Aimmax Therapeutics Inc in Durham, North Carolina received $4.9 million in federal grants from fiscal 2021 to 2025, across 4 awards. Its largest program was Allergy and Infectious Diseases Research, with $4.9 million. In fiscal 2025 it was awarded $1.0 million.
From USAspending.gov award records, updated October 31, 2026.
- Grants, FY 2021 to 2025$4.9 million
- Awards4
- Awarded in FY 2025$1.0 million
- Largest award$3.4 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 0 | $0 |
| FY 2022 | 2 | $613,401 |
| FY 2023 | 3 | $1.6 million |
| FY 2024 | 3 | $1.6 million |
| FY 2025 | 1 | $1.0 million |
Programs that fund Aimmax Therapeutics Inc
| Program | Awards | Amount |
|---|---|---|
| Allergy and Infectious Diseases Research | 4 | $4.9 million |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 4 | $4.9 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Development of a novel oral antibiotic for the treatment of drug resistant gonorrhea - project summary / abstract the CDC has identified neisseria gonorrhoeae as a pathogen of the highest threat level (“urgent threat”) to the us public health. Currently there is only a single recommended agent remai | Allergy and Infectious Diseases Research | August 8, 2022 | $3.4 million |
| Development of a novel injectable antibiotic to treat serious multidrug-resistant gram-positive infections - project summary / abstract within the past decades, the prevalence of antibiotic-resistant (AMR) gram-positive infections have increased, and gram-positive bacteria cause the majority of noso | Allergy and Infectious Diseases Research | May 4, 2023 | $613,907 |
| Optimization and characterization of novel antifungal peptides - project summary / abstract invasive candidiasis is a disease associated with significant morbidity and mortality, with only 3 classes of antifungals available for treatment. While candida albicans remains the most common species associ | Allergy and Infectious Diseases Research | May 10, 2022 | $612,894 |
| A single dose therapy to treat drug resistant gonorrhea - project summary / abstract gonorrhea is a sexually transmitted infection caused by n. Gonorrhoeae. In recent years, the number of people with gonorrhea infections in the us has steadily increased, with more than 700,000 infections reported in | Allergy and Infectious Diseases Research | March 25, 2024 | $306,497 |
Questions people ask
How much federal grant money does Aimmax Therapeutics Inc get?
$4.9 million in 4 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Aimmax Therapeutics Inc the most?
The Department of Health and Human Services, with $4.9 million in 4 awards.
What is Aimmax Therapeutics Inc's largest federal grant?
$3.4 million under Allergy and Infectious Diseases Research, with its first action in the period on August 8, 2022. That counts only the money obligated in fiscal 2021 to 2025.
Other grant recipients in Durham
- Duke University
- Family Health International
- North Carolina Central University
- Housing Authority of the City of Durham
- Rho Federal Systems Division Inc
- City of Durham
- Families & Communities Rising, Inc.
- Lincoln Community Health Center Incorporated
Largest federal grant recipients in North Carolina · Federal grants in North Carolina